• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

生物类似药进入市场后，医疗保险 B 部分生物药支出的变化。

Changes in Medicare Part B Spending for Biologic Drugs After Biosimilar Entry Into the Market.

机构信息

Department of Health Management and Policy, Miami Herbert Business School, University of Miami, Miami, Florida.

Division of Health Policy and Economics, Department of Population Health Sciences, Weill Cornell Medical College, New York, New York.

出版信息

JAMA Health Forum. 2021 Sep 17;2(9):e212634. doi: 10.1001/jamahealthforum.2021.2634. eCollection 2021 Sep.

DOI:10.1001/jamahealthforum.2021.2634
PMID:35977178
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8796923/
Abstract

This cross-sectional study describes changes in annual Medicare Part B spending for biologic drugs after biosimilar entry, focusing on the first 4 products to experience biosimilar competition: filgrastim, infliximab, epoetin alpha, and pegfilgrastim.

摘要

这项横断面研究描述了生物类似药进入市场后，生物药品医保 B 部分年度支出的变化情况，重点关注最先经历生物类似药竞争的 4 种产品：非格司亭、英夫利昔单抗、重组人红细胞生成素和培非格司亭。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7feb/8796923/dd38ddbd5398/jamahealthforum-e212634-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7feb/8796923/dd38ddbd5398/jamahealthforum-e212634-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7feb/8796923/dd38ddbd5398/jamahealthforum-e212634-g001.jpg

相似文献

1
Changes in Medicare Part B Spending for Biologic Drugs After Biosimilar Entry Into the Market.生物类似药进入市场后，医疗保险 B 部分生物药支出的变化。
JAMA Health Forum. 2021 Sep 17;2(9):e212634. doi: 10.1001/jamahealthforum.2021.2634. eCollection 2021 Sep.
2
Physician, Practice, and Patient Characteristics Associated With Biosimilar Use in Medicare Recipients.与医疗保险受益人中生物类似药使用相关的医生、实践和患者特征。
JAMA Netw Open. 2021 Jan 4;4(1):e2034776. doi: 10.1001/jamanetworkopen.2020.34776.
3
Patient Out-of-Pocket Costs for Biologic Drugs After Biosimilar Competition.生物类似药竞争后生物药的患者自付费用。
JAMA Health Forum. 2024 Mar 1;5(3):e235429. doi: 10.1001/jamahealthforum.2023.5429.
4
Spending on and Use of Clinician-Administered Drugs in Medicare.医疗保险中临床医生管理药物的支出和使用。
JAMA Health Forum. 2023 Sep 1;4(9):e232941. doi: 10.1001/jamahealthforum.2023.2941.
5
Uptake and cost of biosimilar filgrastim among Medicare and Medicaid populations in 2015-2018.2015-2018 年医疗保险和医疗补助人群中生物类似物非格司亭的使用和费用。
J Manag Care Spec Pharm. 2021 May;27(5):660-666. doi: 10.18553/jmcp.2021.27.5.660.
6
Biosimilar Uptake in Medicare Part B Varied Across Hospital Outpatient Departments and Physician Practices: The Case of Filgrastim.百奥泰生物制药股份有限公司
Value Health. 2020 Apr;23(4):481-486. doi: 10.1016/j.jval.2019.12.007. Epub 2020 Feb 17.
7
Association of Generic Competition With Price Decreases in Physician-Administered Drugs and Estimated Price Decreases for Biosimilar Competition.医生管理药物的仿制药竞争与价格下降的关联，以及预计生物类似药竞争带来的价格下降。
JAMA Netw Open. 2021 Nov 1;4(11):e2133451. doi: 10.1001/jamanetworkopen.2021.33451.
8
Biosimilar formulary placement in Medicare Part D prescription drug plans: A case study of infliximab.生物类似药在医疗保险D部分处方药计划中的医保目录准入：英夫利昔单抗案例研究
Am J Health Syst Pharm. 2021 Jan 22;78(3):216-221. doi: 10.1093/ajhp/zxaa376.
9
Filgrastim and infliximab biosimilar uptake in Medicare Advantage compared with Traditional Medicare, 2016-2019.2016-2019 年医疗保险优势计划与传统医疗保险相比，采用非格司亭和英夫利昔单抗生物类似药的情况。
J Manag Care Spec Pharm. 2024 Jan;30(1):15-21. doi: 10.18553/jmcp.2024.30.1.15.
10
Biosimilar Uptake in Academic and Veterans Health Administration Settings: Influence of Institutional Incentives.学术和退伍军人健康管理局环境中的生物类似药采用：机构激励的影响。
Arthritis Rheumatol. 2020 Jul;72(7):1067-1071. doi: 10.1002/art.41277. Epub 2020 May 5.

引用本文的文献

1
Role of supply chain intermediaries in steering hospital product choice: Group Purchasing Organizations and biosimilars.供应链中介机构在引导医院产品选择中的作用：集团采购组织与生物类似药
Health Aff Sch. 2024 May 15;2(6):qxae067. doi: 10.1093/haschl/qxae067. eCollection 2024 Jun.

本文引用的文献

1
Biosimilar Cost Savings in the United States: Initial Experience and Future Potential.美国生物类似药的成本节约：初步经验与未来潜力
Rand Health Q. 2018 Mar 30;7(4):3. eCollection 2018 Mar.
2
Biosimilars-Curb Your Enthusiasm.生物类似药——抑制你的热情。
JAMA Oncol. 2017 Nov 1;3(11):1467-1468. doi: 10.1001/jamaoncol.2017.1530.